Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Arthritis & Rheumatism

• Publication date

  2010-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/art.27670PMID 20662054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.

  2010cited by this paper
• Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis

  2010cited by this paper
• The time has come to limit the placebo period in rheumatoid arthritis trials to 3 months: a systematic comparison of 3- and 6-month response rates in trials of biological agents

  2009cited by this paper
• Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

  2009cited by this paper
• Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

  2008cited by this paper
• Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis.

  2008cited by this paper
• Performing trials in children with rheumatic diseases: comment on the editorial by Lehman.

  2008cited by this paper
• Are withdrawal trials in paediatric rheumatic disease helpful?

  2008cited by this paper
• Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

  2008cited by this paper
• The time has come to include assessment of radiographic progression in juvenile idiopathic arthritis clinical trials.

  2008cited by this paper
• The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study.

  2008cited by this paper
• Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis.

  2008cited by this paper
• Adalimumab in juvenile rheumatoid arthritis.

  2008cited by this paper
• Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

  2008cited by this paper
• A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

  2007cited by this paper
• The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis

  2007cited by this paper
• Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis.

  2007cited by this paper
• The future of pediatric rheumatology: many questions remain.

  2007cited by this paper
• Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis.

  2007cited by this paper
• Use of the Sharp and Larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis.

  2006cited by this paper
• The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement.

  2006cited by this paper
• Development of a standardized method of assessment of radiographs and radiographic change in juvenile idiopathic arthritis: introduction of the Dijkstra composite score.

  2005cited by this paper
• PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it

  2005cited by this paper
• A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results.

  2005cited by this paper
• Leflunomide or methotrexate for juvenile rheumatoid arthritis.

  2005cited by this paper
• Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.

  2004cited by this paper
• International research networks in pediatric rheumatology: the PRINTO perspective

  2004cited by this paper
• A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.

  2004cited by this paper
• The randomized placebo-phase design for clinical trials.

  2003cited by this paper
• Preliminary definition of disease flare in juvenile rheumatoid arthritis.

  2002cited by this paper
• Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology.

  2001cited by this paper
• The randomized placebo-phase design for clinical trials

  2001cited by this paper
• Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

  2000cited by this paper
• Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

  2000cited by this paper
• Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate.

  1998cited by this paper
• Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.

  1998cited by this paper
• Preliminary definition of improvement in juvenile arthritis.

  1997cited by this paper
• Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatric Rheumatology Collaborative Study Group.

  1996cited by this paper
• Use of placebo controls in clinical trials disputed.

  1995cited by this paper
• Guidelines for the Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations

  1995cited by this paper
• The continuing unethical use of placebo controls.

  1994cited by this paper
• Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group.

  1992cited by this paper
• Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial.

  1986cited by this paper
• A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis.

  1986cited by this paper
• A FORTRAN program for the design and analysis of sequential clinical trials.

  1983cited by this paper

• Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab.

  2026cites this paper
• Impact of Concomitant Methotrexate Use and Prior Biologic Disease‐Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial

  2025cites this paper
• Serum biomarkers associated with baricitinib response in patients with juvenile idiopathic arthritis: a post-hoc analysis of the phase 3 JUVE-BASIS trial.

  2025cites this paper
• Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting

  2025cites this paper
• Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review

  2023cites this paper
• Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.

  2023cites this paper
• A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis

  2022cites this paper
• Juvenile idiopathic arthritis

  2022cites this paper
• Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

  2022cites this paper
• Long-term Efficacy and Safety of Canakinumab in the Treatment of Systemic Juvenile Idiopathic Arthritis in Japanese Patients: Results from an Open-label Phase III Study.

  2022cites this paper
• “To Randomize, or Not to Randomize, That is the Question”

  2021cites this paper
• Pharmacosurveillance in Juvenile Idiopathic Arthritis.

  2021cites this paper
• Real-world or clinical trial data for treatment of children with rheumatic diseases?

  2020cites this paper
• Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study

  2020cites this paper
• Different corticosteroid induction regimens in children and young people with juvenile idiopathic arthritis: the SIRJIA mixed-methods feasibility study.

  2020cites this paper
• Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients

  2020cites this paper
• Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial

  2020cites this paper
• (2020). Real-world or clinical trial data for treatment of children with rheumatic diseases? Rheumatology, 59(4),

  2020cites this paper
• Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study

  2019cites this paper
• Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis

  2019cites this paper
• The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

  2018cites this paper
• Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities

  2018cites this paper
• Protective parents and permissive children: what qualitative interviews with parents and children can tell us about the feasibility of juvenile idiopathic arthritis trials

  2018cites this paper
• Current and future perspectives in the management of juvenile idiopathic arthritis.

  2018cites this paper
• Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial

  2017cites this paper
• Recent therapeutic advances in juvenile idiopathic arthritis.

  2017cites this paper
• Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases

  2017cites this paper
• Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.

  2017cites this paper
• Clinical Trial Design in Juvenile Idiopathic Arthritis

  2017cites this paper
• Trial Design and Collaborative Work in Pediatric Rheumatology

  2017cites this paper
• Efficacy and Safety of Pharmacological and Non-Pharmacological Interventions in Juvenile Idiopathic Arthritis: A Series of Systematic Reviews and Network Meta-Analyses

  2017cites this paper
• Chapter 7 – Juvenile Idiopathic Arthritis

  2017cites this paper
• Refractory autoimmune disease: an overview of when first-line therapy is not enough.

  2016cites this paper
• General treatment aspects

  2016cites this paper
• A Meta‐Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis

  2016cites this paper
• Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials.

  2016cites this paper
• The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.

  2016cites this paper
• Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

  2016cites this paper
• Heading Toward a Modern Imaging Approach in Juvenile Idiopathic Arthritis

  2014cites this paper
• Juvenile idiopathic arthritis and malignancy.

  2014cites this paper
• Methodology of clinical trials for rare diseases.

  2014cites this paper
• Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial

  2014cites this paper
• Translational medicine from bedside to bench and back again: methotrexate revisited

  2013cites this paper
• Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design?

  2013cites this paper
• It Is Worth Including Assessment of Disease Activity State in Juvenile Arthritis Clinical Trials

  2013cites this paper
• Impact of the European paediatric legislation in paediatric rheumatology: past, present and future

  2013cites this paper
• Infectious Complications in Juvenile Idiopathic Arthritis

  2013cites this paper
• Creative trial design in RA: optimizing patient outcomes

  2013cites this paper
• Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept

  2013cites this paper
• Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis

  2013cites this paper
• Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis

  2012cites this paper
• MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis

  2012cites this paper
• A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

  2012cites this paper
• Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score.

  2012cites this paper
• Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

  2012cites this paper
• Toward a treat-to-target approach in the management of juvenile idiopathic arthritis.

  2012cites this paper
• A strategic revolution in HIV and global health.

  2011cites this paper
• Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)

  2011cites this paper
• Juvenile idiopathic arthritis.

  2011cites this paper
• Clinical and epidemiological research

  2011cites this paper
• Emerging drugs to treat juvenile idiopathic arthritis

  2011cites this paper
• Current Medical Treatments for Juvenile Idiopathic Arthritis

  2011influential citation
• A European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA)

  2011cites this paper
• Juvenile Idiopathic Arthritis

  2000cites this paper
• Ef fi cacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study

  year unknowncites this paper